Literature DB >> 3092888

The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.

P Thiagarajan, V Pengo, S S Shapiro.   

Abstract

We describe here a test for lupus anticoagulants based on a modified Russell viper venom time (RVVT), using limiting amounts of phospholipid and venom. We have studied 29 patients with a prolonged dilute RVVT. Five of the 29 had a normal activated partial thromboplastin time and three of 14 tested by the tissue thromboplastin inhibition test were normal. In 17 of 19 patients tested, the dilute RVVT was completely normal when ionophore-treated platelets were substituted for phospholipid; the remaining two patients, both with very long phospholipid-dependent dilute RVVT's, were nearly completely normalized. The dilute RVVT is not prolonged in the presence of antibodies to factors VIII, IX, or XI. Thus, the dilute RVVT appears to be a simple, reproducible, sensitive, and relatively specific method for the detection of lupus anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092888

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment.

Authors:  M Schwartz; M Rochas; E Toubi; B Sharf
Journal:  J Psychiatry Neurosci       Date:  1999-09       Impact factor: 6.186

2.  Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. The Lupus Anticoagulant Working Party.

Authors: 
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

Review 3.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Lupus cofactor phenomenon.

Authors:  M Magrath
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

5.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

6.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

7.  Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

8.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

9.  [21-year-old patient with myocardial infarct, transient cerebral ischemia and thrombocytopenia].

Authors:  A Rank; L Lindner; E Hiller
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

Review 10.  Laboratory evaluation of a bleeding patient.

Authors:  R O Wallerstein
Journal:  West J Med       Date:  1989-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.